Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Korea's Ildong Pharmaceutical Wins License To Sell Shionogi's IPF Drug In Korea

This article was originally published in PharmAsia News

Executive Summary

SEOUL - South Korea's Ildong Pharmaceutical Co., Ltd. said it plans to launch Shionogi & Co., Ltd.'s idiopathic pulmonary fibrosis product Pirespa (pirfenidone) in Korea in the first half of 2012 under an in-licensing deal signed July 11
Advertisement

Related Content

Korea's Hyundai Introduces Emergency Contraceptive ellaOne To Asia With No Additional Post-marketing Requirements
Korea's Hyundai Introduces Emergency Contraceptive ellaOne To Asia With No Additional Post-marketing Requirements
In Medical Tourism Drive, Korea's JW Choongwae Links Up With Kazakhstan's JSC Chempharm To Build Manufacturing Plant
In Medical Tourism Drive, Korea's JW Choongwae Links Up With Kazakhstan's JSC Chempharm To Build Manufacturing Plant
BMS Bets On Amira's IPF Drug In $325M Acquisition
BMS Bets On Amira's IPF Drug In $325M Acquisition
Merck Turns Again To Daewoong For Co-promotion In South Korea
Advertisement
UsernamePublicRestriction

Register

SC078582

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel